Country: South Africa
Language: English
Source: South African Health Products Regulatory Authority (SAHPRA)
Alcon
CIPROBAY® HC OTIC DROPS SCHEDULING STATUS: S4 PROPRIETARY NAME (and dosage form): CIPROBAY ® HC OTIC DROPS Ear drops COMPOSITION Each mL contains ciprofloxacin hydrochloride equivalent to 2 mg ciprofloxacin base and 10 mg hydrocortisone , with benzyl alcohol 0.9% (m/v) as preservative. A single 3-drop dose contains approximately 300 micrograms ciprofloxacin and 1.5 mg of hydrocortisone. PHARMACOLOGICAL CLASSIFICATION A 16.2 Aural preparations, ear drops. PHARMACOLOGICAL ACTION Ciprofloxacin is a broad-spectrum fluoroquinolone antibiotic with proven activity against bacteria causing bacterial otitis externa. Hydrocortisone is a corticosteriod with a range of anti-inflammatory properties. Ciprofloxacin acts by inhibiting bacterial DNA gyrase. In vitro susceptibility data for species where clinical efficacy has been demonstrated, include Enterobacteriaceae, Pseudomonas aeruginosa andStaphylococcus aureus. Sensitivity testing should be performed before treatment is initiated. Anaerobes are usually resistant. A single 3-drop dose of CiproBay ® HC otic dropsdelivers approximately 300 micrograms of ciprofloxacin, giving local concentrations well in excess of the MICs for the pathogens associated with bacterial otitis externa. Predicted ciprofloxacin serum concentrations after ototopic administration of a 0.2% ciprofloxacin formulation (total dose per application approximately 300 microgramms) would be below the existing assay detection limits (limit of quantification 5 micrograms/L). Even if full absorption of the topical dose were seen, peak ciprofloxacin concentrations of only approximately 3 microgramms/L would be expected at steady state, based on data for oral administration. Data shows that there were no measurable plasma concentrations of ciprofloxacin after ototopic administration of a 0.3% cipr Read the complete document